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Abstract 16 
Cytochrome P450 (CYP) enzymes catalyze the insertion of oxygen into carbon-17 
hydrogen bonds and have great potential for enzymatic synthesis. Application development 18 
of class I CYPs is hampered by their dependence on two redox partners (a ferredoxin and 19 
ferredoxin reductase), slowing catalysis compared to self-sufficient CYPs such as CYP102A1 20 
(P450BM3). Previous attempts to address this have fused all three components in several 21 
permutations and geometries, with much reduced activity compared to the native system. We 22 
report here the new approach of fusing putidaredoxin reductase (PdR) to the carboxy-23 
terminus of CYP101A1 (P450cam) via a linker peptide and reconstituting camphor 24 
hydroxylase activity with free putidaredoxin (Pdx). Initial purification of a P450cam-PdR 25 
fusion yielded 2.0% heme incorporation. Co-expression of E. coli ferrochelatase, lengthening 26 
the linker from 5 to 20 residues, and altering culture conditions for enzyme production 27 
furnished 85% heme content. Fusion co-expression with Pdx gave a functional system with 28 
comparable in vivo camphor oxidation activity as the native system. In vitro, the fused 29 
system’s steady state NADH oxidation rate was two-fold faster than that of the native system. 30 
In contrast to the native system, NADH oxidation rates for the fusion enzyme showed non-31 
hyperbolic dependence on Pdx concentration, suggesting a role for the PdR domain; these 32 
data were consistent with a kinetic model based on two-site binding of Pdx by P450cam-PdR 33 
and inactive dimer formation of the fusion. P450cam-PdR is the first example of a class I 34 
P450 fusion that exhibits significantly more favorable behavior than that of the native system. 35 
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Introduction 45 
The heme-dependent cytochrome P450 (CYP) superfamily of monooxygenases are found in 46 
most domains of life,1 from hepatocytes2 and mitochondria,3 through plants,4 nematodes,5 and 47 
bacteria,6, 7 to protozoa,8, 9 and viruses.10 Their varied provenances mirror their varied 48 
functions; even within a particular species, several P450s with differentiated activities and 49 
specificities can be found, testament to the biological importance of insertion of an oxygen 50 
atom into a carbon-hydrogen bond, the fundamental reaction commonly catalyzed by these 51 
enzymes.11  52 
CYP systems solve the problem of delivering the two necessary reducing equivalents 53 
from NAD(P)H to the cytochrome synchronously with its hydroxylating catalytic cycle in 54 
several ways.11 Eukaryota employ several permutations of fused redox domains and Bacteria 55 
and mitochondria often, but not exclusively, rely on shuttle ferredoxins to provide electrons.12 56 
Bacterial class I CYP systems are commonly composed of an FAD-dependent ferredoxin 57 
reductase, and a [2Fe-2S]-dependent ferredoxin, and the terminal P450 monooxygenase (Fig. 58 
1A).13 Each of these components is usually highly specific, ensuring tight regulation of 59 
electron transport and preventing cross talk between multiple systems in the same cell. The 60 
three-component nature of these systems generates inherent kinetic impedance for substrate 61 
oxidation when compared to one- (e.g. CYP102A1 (P450BM3) from Bacillus megaterium14) 62 
or two-component CYP systems (e.g. vertebrate hepatic CYP3A415) since electron transfer is 63 
intermolecular rather than largely intramolecular. As a shuttle protein, the class I ferredoxins 64 
must be able to recognize and bind both the ferredoxin reductase and CYP enzyme to give 65 
[2Fe-2S]:heme or [2Fe-2S]:FAD orbital overlap for a physiologically appropriate rate of 66 
electron transfer. Under physiological conditions, the first electron transfer to the ferric, 67 
substrate-bound CYP from the reduced ferredoxin controls the NAD(P)H-oxidation and 68 
substrate hydroxylation rates of class I systems.  69 
The most studied class I cytochrome P450 is the camphor 5-hydroxylase P450cam 70 
(CYP101A1) from Pseudomonas putida. P450cam and its cognate electron transfer 71 
partners—the FAD-dependent putidaredoxin reductase (PdR) and the [2Fe-2S] putidaredoxin 72 
(Pdx)—have been structurally characterized.16-20 As a result of the extensive body of 73 
biochemical and structural data, the P450cam system is considered the model of the bacterial 74 
class I CYPs, despite its idiosyncrasies.21 This class contains a multitude of other CYPs with 75 
potential for biotechnological applications but their kinetic properties inhibit widespread 76 
development.22 Numerous CYPs are not genetically associated with their physiological 77 
electron transfer partners, including those from metagenomic libraries. Activity reconstitution 78 
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relies on the opportune activity of known CYP-associated ferredoxins such as Pdx,23, 24 and 79 
adrenodoxin (Adx) associated with the mitochondrial CYP11A1 (P450scc),25-30 amongst 80 
others.31-36 If these problems were resolved, processes could be facilitated in fields as diverse 81 
as fine chemicals and pharmaceuticals,37 e.g. in vitro synthesis of antibiotics by uncultivable 82 
soil bacteria might become viable.38, 39  83 
Previous approaches have mimicked the naturally fused CYPs.40, 41 Every permutation 84 
of a chain of P450cam, Pdx and PdR was constructed and expressed (Fig. 1B); all such 85 
fusions showed slower in vivo camphor biotransformation than the native system.42 The 86 
P450cam system components have been attached to a synthetic non-natural ternary linker;43 87 
in other work, they were fused to the subunits of proliferating cell nuclear antigen (PCNA), a 88 
hetero-trimer from Sulfolobus solfataricus, to form a self-assembling, branched super-89 
enzyme (Fig. 1C).44,45, 46 These approaches illustrated the importance of flexibility in such 90 
class I fusion systems to allow potentially orthogonal binding orientations between redox 91 
partners for efficient electron shuttling by the ferredoxin. Class I CYPs have also been fused 92 
to the carboxy-terminus of the reductase domain of P450Rhf from Rhodococcus rhodochrous 93 
(Fig. 1D), but electron transfer rates were low.47,48  94 
Since fusion of complete systems had seen limited success, we explored the creation 95 
of fusions using only a subset of the P450cam system components, namely PdR and P450cam 96 
(Fig. 1E), and investigated the electron transfer and camphor oxidation kinetics of the system 97 
in vivo and in vitro. Partial fusion of CYP system enzymes has been reported: PdR was 98 
chemically cross-linked to Pdx, which improved camphor hydroxylation kinetics at saturating 99 
P450cam concentrations.49 However, fusing of indirect redox partners has not been 100 
described. After constructing a series of expression plasmids and optimizing conditions for 101 
production of a maximally heme-incorporated P450cam-PdR fusion enzyme, we found that 102 
this fused system oxidized DL-camphor identically to the native system in vivo. We 103 
demonstrated enhanced electron transfer, and found that NADH oxidation in vitro showed 104 
non-Michaelis-Menten dependence on Pdx concentration, which could be modeled by 105 
considering an extended two-site sequential binding model that incorporates two distinct Pdx 106 
binding sites and inactive dimerization of the fully Pdx-bound P450cam-PdR fusion. 107 
 108 
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Materials and methods 111 
Molecular biology 112 
Genes encoding P450cam and PdR had previously been cloned into expression plasmids.50 113 
The camC gene was amplified with primers incorporating NcoI and SacI restriction sites and 114 
a sequence encoding a carboxy-terminal AAKKT linker (linker A, LA), while primers 115 
incorporating SacI and HindIII sites were used to amplify camA. Amplified fragments were 116 
assembled in the Multiple Cloning Site 1 (MCS1) of an NcoI/HindIII-linearized pRSFDuet-1 117 
vector in a three-piece ligation step. This pRSFDuet::camC-LA-camA construct is referred to 118 
as pFusion. 119 
E. coli ferrochelatase, encoded by hemH, was amplified from genomic DNA, which 120 
had been isolated using the Promega Genomic DNA Miniprep kit according to the 121 
manufacturer’s instructions. PCR primers incorporating NdeI and XhoI restriction sites 122 
allowed ligation into the MCS2 of NdeI/XhoI-linearized pFusion to create the recombinant 123 
plasmid pRSFDuet::camC-LA-camA::hemH, or pFusionH. 124 
The original AAKKT linker in pFusionH was replaced with the sequence 125 
DVSTEQSAKEAPAETLGAFR (linker 2, L2) by the MEGAprimer WHOle Plasmid 126 
(MEGAWHOP) method.51, 52 pFusionH was linearized by inverse PCR, which excluded the 127 
linker region. Exactly complementary oligonucleotides containing the sequence encoding L2 128 
and a ca. 10-nt 5′- and 3′-overlap with the linearized plasmid was synthesized (Eurofins 129 
MWG Biotech, Germany) and used as a primer pair to amplify the linearized plasmid (Table 130 
S1). After DpnI digest, the PCR product (a doubly-nicked plasmid) was then used to 131 
transform E. coli DH5α, from which the intact plasmid pRSFDuet::camC-L2-camA 132 
(pFusionH2), was extracted and the insert sequences confirmed by Sanger sequencing 133 
(Source Bioscience, UK). 134 
Expression and purification of P450cam, Pdx, and PdR 135 
The camC gene encoding the non-dimerizing P450cam mutant C334A was used throughout, 136 
and is referred to as the native enzyme.53 Expression plasmids harboring the camA, camB and 137 
camC genes, encoding the PdR, Pdx, and native P450cam enzymes, respectively, had 138 
previously been constructed in our laboratory. The expression and purification of these 139 
proteins have already been described.54, 55 140 
Expression and purification of fused P450cam-PdR enzymes 141 
A colony of E. coli BL21 (DE3) transformed with the appropriate pFusion plasmid and 142 
grown on LB agar containing 30 µg mL–1 kanamycin (kan) was used to inoculate a starter 143 
culture of TB containing 30 µg mL–1 kan (TBkan). This culture was grown until OD600 was 144 
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0.5–0.8 and used to inoculate a large-scale TBkan culture at 2% v/v. The large culture was 145 
grown at 37 °C and 200 rpm until OD600 was 0.6–0.8. The temperature was then reduced to 146 
20 °C, and shaking was reduced to 100 rpm. The culture was supplemented with 1 mM 5-147 
aminolevulinic acid (δ-ALA), 0.1 mM riboflavin, 4 mM ammonium ferric citrate (AFC), and 148 
1 mM DL-camphor from a 100 mM stock in ethanol. After two hours, enzyme production 149 
was induced with 40 µM isopropyl β-D-1-thiogalactopyranoside (IPTG). 150 
Expression was continued for 72 h, or until the culture reached saturation (OD600 ≈ 8), 151 
at which point the cells were harvested by centrifugation at 4000 × g and 4 °C, before being 152 
stored at −20 oC. To extract the fusion enzyme, cells were thawed at 4 °C and then 153 
resuspended in 10 mM Tris-HCl, pH 7.4, supplemented with 20% v/v glycerol, 1% v/v Triton 154 
X-100, 1 mM DTT, 0.5% v/v b-mercaptoethanol (BME), 1 mM camphor, and 0.1 mg mL−1 155 
lysozyme from chicken egg white (Sigma-Aldrich, UK), ensuring cell wet weight was ≤ 20% 156 
w/v of the final suspension. This suspension was incubated at 4 °C for 2 h before cells were 157 
lysed by sonication. Cell debris were removed by centrifugation at 39,000 × g and 4 °C. 158 
The cell-free lysate was loaded onto a 200 × 50 mm DEAE-Sepharose (GE 159 
Healthcare, UK) column and eluted with a gradient of 60–200 mM KCl (P450cam-LA-PdR), 160 
or 80–230 mM KCl (P450cam-L2-PdR) in 50 mM Tris-HCl pH 7.4, supplemented with 1 161 
mM camphor. Red-colored fractions were then concentrated by ultrafiltration and desalted on 162 
a 500 mL bed-volume Sephadex G-25 (GE Healthcare, UK) column, which had been 163 
equilibrated in 50 mM Tris-HCl, pH 7.4. 164 
Eluate from the G-25 column was concentrated by ultrafiltration and applied to a 120 165 
× 26 mm Source 15Q column (GE Healthcare), and eluted with a gradient of 50–700 mM 166 
KCl (P450cam-LA-PdR) or 100–750 mM KCl (P450cam-L2-PdR) in 50 mM Tris-HCl, pH 167 
7.4. The purest fractions, as indicated by A420/A280 ≥ 1, were pooled, concentrated to ca. 100 168 
µM, and filtered through a 0.22 µm sterile syringe filter. Sterile glycerol was added to 50% 169 
v/v for storage at −20 °C. Glycerol was removed immediately prior to experiments by gel 170 
filtration on a PD-10 column (GE Healthcare, UK) equilibrated with 40 mM phosphate 171 
buffer, pH 7.4. The P450 content was determined by the CO-difference spectrum method and 172 
using e450–490 = 91 mM–1cm–1.56, 57 173 
Camphor-binding titrations 174 
All titrations were performed at 30 ± 0.5 °C. P450cam or P450cam-L2-PdR was diluted to 2–175 
5 µM using 40 mM phosphate, pH 7.4, in 2.5 ml, and 0.5–2 µL of DL-camphor was added 176 
using a Hamilton syringe from a 1, 10, or 100 mM stock solution in ethanol. After mixing, 177 
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the peak-to-trough absorbance difference, ΔA, was recorded on a Cary 50 spectrophotometer 178 
between 700 nm and 250 nm. Further aliquots of camphor were added until ΔA did not 179 
change further. The observed ΔA values were scaled for dilution, and the dissociation 180 
constant, Kd, for camphor binding was obtained by fitting the scaled ΔA to the camphor 181 
concentration using a rectangular hyperbola: ΔA = ΔAmax × [camphor]/(Kd + [camphor]). The 182 
titrations were repeated with 200 mM KCl added from a 2 M stock solution in 40 mM 183 
phosphate, pH 7.4 before the addition of camphor aliquots. 184 
Potassium-binding titrations 185 
Potassium binding titrations were carried out in 50 mM Tris-HCl buffer, pH 7.4, in 2.5 ml. 186 
The P450cam-L2-PdR fusion was buffer exchanged to the Tris-HCl buffer by elution through 187 
a PD-10 column. DL-Camphor was added as a 100 mM stock solution in ethanol to a final 188 
concentration of 1 mM. Aliquots of a 2 M stock of KCl in 50 mM Tris-HCl, pH 7.4, were 189 
added and the difference spectrum recorded until a final KCl concentration of 200 mM. The 190 
peak-to-trough difference ΔA was scaled to account for dilution and the dissociation constant, 191 
Kd, for potassium binding was determined by fitting the scaled ΔA values to KCl 192 
concentration using a rectangular hyperbola: ΔA = ΔAmax × [KCl]/(Kd + [KCl]).  193 
Camphor biotransformation 194 
E. coli BL21 (DE3) cells were co-transformed with an appropriate pFusion plasmid and 195 
pCW::camB, and an isolated colony from the LBamp/kan agar plate was used to inoculate 196 
LBamp/kan medium. The culture was shaken overnight at 37 °C and 200 rpm, and then used to 197 
inoculate a large-scale TBamp/kan culture at 10% v/v. After 5 h at 37 °C and 200 rpm, 1 mM 5-198 
aminolevulinic acid (δ-ALA), 0.1 mM riboflavin, 4 mM and ammonium ferric citrate (AFC) 199 
were added and the temperature was lowered to 30 °C. After one hour, 40 µM IPTG was 200 
added to induce expression of the camphor-oxidation system at 30 °C and 200 rpm for 16 h. 201 
After centrifugation at 4000 × g and 4 °C for 10 min, cell pellets were resuspended in 202 
20% of their original culture volume in TBamp/kan containing 1% w/v glucose. The P450 203 
content was ca. 20 nM in both the fusion and native whole cell reactions after 24 h. The 204 
culture was transferred to 2 L baffled flasks, with 200 mL culture per flask. DL-camphor was 205 
added to 4 mM from a 100 mM stock in ethanol. Aliquots of 900 µL samples of culture were 206 
taken at several time points up to 24 h. 9-Hydroxyfluorene (75 µM) was added as an internal 207 
standard and the sample was extracted with 400 µL ethyl acetate.50 After phase separation by 208 
centrifugation at 13,400 × g for 1 min the organic phase was analyzed on a ThermoFinnegan 209 
Trace GC instrument equipped with a flame ionization detector, an AutoSampler AS3000 and 210 
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a 30 m DB-1 fused silica column (0.32 mm diameter, 0.25 µm film thickness). The oven 211 
temperature was held at 80 °C for 1 min then increased to 220 °C over 9 min, and held at 220 212 
°C for 2 min. Helium was used as the carrier gas. The 24 h extracts were also analyzed by 213 
GC-MS to confirm product identities. 214 
Serially diluting an aqueous indole (Sigma-Aldrich, UK) solution in volumetric flasks 215 
generated a series of indole standards spanning 75 µM to 2.4 mM. Ethyl acetate extracts of 216 
these standards were prepared as above; the resultant GC chromatograms were used to 217 
calculate a standard curve of the detector response normalized to internal standard against 218 
indole concentration. 219 
NADH turnover assays 220 
All turnover assays were carried out using a Cary 50 spectrophotometer at 30.0 ± 0.5 °C in a 221 
1.2 mL solution of 40 mM phosphate buffer, pH 7.4. Bovine liver catalase (100 µg mL–1) was 222 
added to all reactions containing DL-camphor. Mixtures were allowed to equilibrate for 2 223 
min before reaction initiation. 224 
Steady state NADH oxidation assays were performed in triplicate using 0.5 µM PdR, 225 
5 µM Pdx, and 0.5 µM P450cam, or 5 µM Pdx and 0.5 µM P450cam-L2-PdR fusion. NADH 226 
was added to ca. 320 µM to give A340 = 2. The reaction was initiated by adding 1 mM DL-227 
camphor from a 100 mM ethanol stock, and A340 was monitored. NADH oxidation rate was 228 
calculated using ε340 = 6.22 mM−1 cm−1. 229 
Pdx titrations for NADH oxidation were performed in triplicate using 0.1 µM 230 
P450cam with 0.5 µM PdR, or 0.1, 0.5, or 1.0 µM P450cam-L2-PdR fusion with and without 231 
0.4 µM PdR. NADH was added as above. The reaction was initiated by adding 1 mM DL-232 
camphor from a 100 mM ethanol stock, and A340 was monitored. NADH oxidation rate was 233 
calculated as above. Titrations against native P450cam produced a good non-linear least 234 
squares fit to the Michaelis-Menten model; those against the fusion displayed non-Michaelis-235 
Menten behavior, and were initially analyzed by ordinary least squares fitting of the Hanes-236 
Woolf rearrangement of the Michaelis-Menten model: [Pdx] / ν = [Pdx] / kcat[Fus] + Km / 237 
kcat[Fus]. 238 
Ferricyanide was used as the terminal electron acceptor to measure NADH oxidation 239 
by PdR or the PdR domain of the fused P450cam-L2-PdR enzyme. The reaction mixture 240 
contained 10 nM PdR or P450cam-PdR. NADH was added as above. The reaction was 241 
initiated by adding 1 mM K3Fe(CN)6. A420 was monitored over time, and K3Fe(CN)6 242 
reduction rates were calculated using ε420 = 1.04 mM−1 cm−1. 243 
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Spectral decomposition 244 
Samples of pure P450cam and PdR were used to generate UV-visible spectra standards, 245 
which were used as a basis set for spectral decomposition of the UV-visible spectrum of the 246 
P450cam-PdR fusions, allowing calculation of heme incorporation. Briefly, the spectrum of 247 
the fusion protein was treated as a vector of absorbance values, for which the contribution 248 
from P450cam and PdR was calculated by solving the system of linear equations in Eq. 1 to 249 
find c, where a is a vector of length m corresponding to the absorbance measurements of the 250 
fusion at m wavelengths, E is a 2 × m matrix containing the absorbances of the standards, and 251 
c is a vector of length 2 containing the relative contribution from each standard. 252 
a = Ec      Eq. 1 253 
Since E is not a square matrix, this system cannot be solved using c = E–1a. However, the 254 
relation in Eq. 2 may be used. If the e1j are the P450cam absorbances and the e2j are the PdR 255 
absorbances, then heme incorporation was calculated by 100 × c1/c2. 256 
c = (ETE)–1ETa    Eq. 2 257 
 258 
  259 
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Results and discussion 260 
Production and purification of fused P450cam-PdR  261 
Previous reports of CYP fusions suggested pivotal and unpredictable effects of both the 262 
length and nature of the linker.42, 43 The plasmid pRSFDuet-1, with two multiple cloning sites 263 
(MCS) each downstream of a T7-promoter, was used for heterologous expression in E. coli. 264 
The genes encoding PdR and P450cam-C334A were assembled with a five amino-acid linker 265 
(LA, sequence AAKKT, Fig. 2A & 2B, Table S1) in MCS1 of pRSFDuet-1 to produce the 266 
construct pRSFDuet::camC-LA-camA (pFusion, Fig. 2C). Previous studies had shown the 267 
benefit of expressing hemoproteins in the presence of ferrochelatase (HemH).58 The E. coli 268 
hemH gene was amplified and cloned into MCS2 of pFusion to give the pFusionH construct 269 
pRSFDuet::camC-LA-camA::hemH. 270 
The linker AAKKT was chosen because previous work on the crystal structure of 271 
fused CYP11A1 and Adx showed that it produced a good compromise between stability and 272 
activity.59 However, since the fusions in the present study were instead between CYP 273 
(P450cam) and reductase (PdR) domains, a second linker was designed to mimic that found 274 
in P450BM3, a natural fusion of a diflavin reductase domain and a CYP domain.14 This 275 
linker (L2) had the sequence DVSTEQSAKEAPAETLGAFR and led to the construct 276 
pRSFDuet::camC-L2-camA::hemH (pFusionH2, Fig. 2C). 277 
After inducing P450cam-LA-PdR expression from pFusion, enzyme purification 278 
followed the typical protocol for P450cam isolation.54 Spectral decomposition of the UV-279 
visible spectrum of the product against P450cam and PdR standards indicated that the fusion 280 
enzyme was severely heme-depleted, showing heme incorporation of 2.0% (Fig. 3A). To 281 
improve heme incorporation, supplementation of the culture medium was explored (Table 1). 282 
Initial supplementation with 100 µM d-ALA, the committed heme precursor, and iron in the 283 
form of 10 µM FeCl2, gave a modest increase in heme content to 5.8% (Fig. 3B). Increasing 284 
the d-ALA concentration to 500 µM raised the heme content to 26% while FeCl2 at 50 µM 285 
had a similar effect (6.9% heme content) as combining 100 µM d-ALA with 10 µM FeCl2. 286 
Addition of 1 mM DL-camphor on its own, without other supplements, resulted in much 287 
higher heme incorporation (31%). On the other hand the presence of 2 mM Na2EDTA 288 
reduced heme assimilation to 8.6%. These observations indicated that higher heme flux from 289 
supplementing with d-ALA and FeCl2 and stabilization of the P450cam fold by camphor 290 
binding increased holoenzyme production, while binding of iron by EDTA4– lowered the 291 
heme flux and hence reduced the production of active enzyme. The pFusionH construct, 292 
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which co-expressed ferrochelatase, furnished a heme content of 22% in the presence of 100 293 
µM d-ALA, a significant improvement over the 5.8% heme content using pFusion. 294 
Similar trends in heme content with culture conditions were observed with the fusion 295 
containing the longer L2 linker (data not shown). A set of conditions for higher heme 296 
incorporation into P450cam-PdR fusions was established as follows: the concentration of iron 297 
in the culture medium during fusion expression was raised to 4 mM by using the non-toxic 298 
soluble iron source ammonium ferric citrate (AFC), with 1 mM DL-camphor to stabilize the 299 
P450cam structure, 1 mM of the heme precursor δ-ALA, 100 µM riboflavin to promote FAD 300 
synthesis, and co-expression of HemH. Under these conditions the pFusionH2 construct 301 
yielded the P450cam-L2-PdR fusion enzyme with 85% heme incorporation (Table 1, Fig. 302 
3D). This enzyme was used for biochemical investigations. 303 
 304 
In vivo activity of the P450cam-L2-PdR fusion 305 
The activity of the fused (P450cam-L2-PdR, Pdx) and native (P450cam, Pdx, PdR) systems 306 
for whole-cell biotransformation of DL-camphor was compared over 24 h. E. coli BL21 307 
(DE3) was transformed either with pFusionH2 and pCW::camB, or pRSFDuet::camC::camA 308 
and pCW::camB plasmids and used for in vivo camphor oxidation. SDS-PAGE analysis 309 
showed that pFusionH2-transformed cultures expressed a polypeptide at the expected size of 310 
P450cam-L2-PdR, and that all enzymes necessary to reconstitute camphor 5-hydroxylase 311 
activity were expressed (Fig. S1). Adjusted to the same P450 content, cultures expressing the 312 
fusion enzyme oxidized DL-camphor at a similar rate to the native system (Fig. 4), with both 313 
showing >99% camphor conversion after 1 hour. Interestingly, further oxidation of 5-exo-314 
hydroxycamphor to 5-oxo-camphor by the fusion enzyme was 39% lower than for the native 315 
system. 316 
GC-MS analysis identified indole in the culture supernatants (Fig. 4A & S2), with 4-317 
fold higher concentration in the reaction with the fusion compared to the native system. 318 
When the cell growth and biotransformation were carried out in FBglycerol, a minimal medium, 319 
no indole was detected in either reaction (Fig. S3). It was not clear what caused these 320 
differences. 321 
 322 
In vitro activity of the P450cam-PdR fusion 323 
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The CO-difference spectrum of purified P450cam-L2-PdR fusion enzyme showed the 450 324 
nm Sorét band characteristic of the CYP superfamily (Fig. 5A) with a minor shoulder at 420 325 
nm indicative of a small amount of misfolded hemoprotein.56, 60 326 
The electron transfer property of the PdR domain in the fusion was assessed by the 327 
rate of ferricyanide reduction. For free PdR the rate of electron transfer from the reduced 328 
FAD to the small molecule acceptor Fe(CN)63– is sufficiently fast to provide an indirect 329 
measure of the rate of FAD reduction by NADH.12, 61, 62 The rate constants of FAD reduction 330 
of native PdR (1500 ± 200 s–1) and P450cam-L2-PdR (1550 ± 20 s–1) were identical within 331 
experimental error. 332 
Substrate binding by native ferric P450cam is accompanied by conversion of the 333 
heme from a low- to a high-spin state, as shown by the shift of the Sorét maximum from 419 334 
nm to 390 nm. The fused system also exhibited this characteristic behavior (Fig. 5B & S4). 335 
P450cam is also unusual in displaying cooperative camphor binding with potassium 336 
binding.54, 63 The binding of potassium stabilizes an otherwise unfavorable conformation 337 
around Tyr96 that orientates its phenol side chain into the substrate pocket where it forms a 338 
hydrogen bond with the camphor carbonyl oxygen and tightens camphor binding. The Kd for 339 
camphor binding by the P450cam-L2-PdR fusion in 40 mM phosphate buffer was 7 ± 1 µM 340 
(Fig. 5C), decreasing to 2.04 ± 0.07 µM in the presence of 200 mM KCl. The Kd value for 341 
native P450cam with 200 mM KCl was 1.2 ± 0.1 µM. The Kd for potassium binding by the 342 
fusion was 11.9 ± 0.2 mM (Fig. 5D), compared to 5.4 ± 0.5 mM for native P450cam.54 These 343 
data showed that the potassium binding site was intact in the fusion enzyme and there was 344 
cooperative binding of potassium and camphor. However, the fusion of PdR appeared to 345 
weaken both camphor and potassium binding, possibly also due to occlusion of the active site 346 
or the potassium binding site by the PdR-domain.54, 64 347 
Next, the in vitro NADH oxidation activity of the reconstituted P450cam-L2-PdR 348 
fusion with camphor as substrate was assayed and compared to the native system. When 5 349 
µM Pdx is mixed with 0.5 µM P450cam-L2-PdR, or with 0.5 µM P450cam and 0.5 µM PdR, 350 
the 10:1:1 Pdx:P450cam:PdR ratio results in the first electron transfer from reduced Pdx to 351 
ferric P450cam being rate-determining. The NADH oxidation rates were 7.8 ± 0.3 352 
nmol (nmol P450cam)–1 s–1 and 17.0 ± 0.1 nmol (nmol P450cam-L2-PdR)–1 s–1. Hence, the 353 
fusion accepted electrons from reduced Pdx more than twice as quickly than in the native 354 
system under these conditions. Such an improvement has not been reported for a fused 355 
P450cam enzyme or any other fused class I CYP system. Previous fusions linked the entire 356 
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three-component system into a single polypeptide (Fig. 1B) but recent structural studies of 357 
the Pdx:P450cam complex showed that orientation of the components is a crucial aspect of 358 
efficient electron transfer.19, 65 The C-terminal Trp106 of Pdx is known from structural and 359 
biochemical studies to be critical for the P450cam:Pdx interaction.66 A C-terminal truncated 360 
Adx is more efficient at transferring electrons to and hence reconstitute the activity of non-361 
native CYPs.25, 67, 68 Fusions must be flexible enough to enable the enzymes to adopt optimal 362 
positions relative to each other. It can be envisioned that there might not be sufficient 363 
flexibility in triple fusions for this to occur. With a P450cam-PdR fusion, Pdx would not be 364 
constrained by fusion to another protein. Moreover, the proximity of PdR (from which Pdx 365 
receives an electron) to P450cam (to which Pdx donates an electron) could lead to higher 366 
turnover rates, i.e. a proximity effect. GC analysis of the products of camphor oxidation 367 
catalyzed by the fusion enzyme in vitro (Fig. S5) showed >90 % coupling of NADH-derived 368 
electrons to 5-exo-hydroxycamphor formation, a comparable value to that of the native 369 
system.54 370 
Initial rates of NADH oxidation for the fused and native CYP enzymes were 371 
measured in the presence of 1 mM DL-camphor and varying concentrations of Pdx to assess 372 
the P450cam:Pdx interaction and electron transfer. For assays with native P450cam, an equal 373 
concentration of PdR was also present. Under these conditions the first electron transfer from 374 
Pdxr to ferric P450cam is the slowest step,12 and native P450cam showed single-site 375 
Michaelis-Menten behavior with a kcat of 64 ± 3 s–1 (Fig. 6A).69 On the other hand, the 376 
Hanes-Woolf plot of initial NADH oxidation rate by 0.1 µM P450cam-L2-PdR against Pdx 377 
concentration showed significant deviation from linearity, in particular at low Pdx 378 
concentrations where a distinct up-tick in [Pdx]/ν was observed (Fig. 6B). The apparent kcat 379 
was estimated to be 56.4 s–1 from a single-site fit. The kinetics with fusion concentrations of 380 
0.5 and 1.0 µM showed more pronounced deviation from Michaelis-Menten kinetics, as well 381 
as decreased apparent kcat with increasing fusion enzyme concentration (estimated kcat = 46.2 382 
s–1 at 0.5 µM and 37.55 s–1 at 1.0 µM, Fig. 6B). 383 
Since measurement of the Fdxr-to-CYP electron transfer rate is usually carried out in 384 
the presence of sufficient FdR to ensure that this step is rate determining,70 initial NADH 385 
oxidation rates were measured for 0.1 µM P450cam-L2-PdR, varying concentrations of Pdx, 386 
and 0.4 µM PdR. Under these conditions, the Hanes-Woolf plots were also non-linear, but 387 
with a distinct down-tick in [Pdx]/ν at low Pdx concentrations (Fig. 6C). 388 
 389 
 14 
Development of a kinetic model for fused P450cam-L2-PdR  390 
Increasing the fusion enzyme concentration increased the apparent cooperativity of the 391 
enzyme-Pdx interaction while reducing the apparent kcat, an unusual phenomenon. Since the 392 
two Pdx-binding sites of the P450cam-PdR fusion were not equivalent, usual models (like the 393 
Hill equation) of cooperative multi-site binding were, perhaps not surprisingly, inappropriate. 394 
Instead, a derivative of the sequential-binding kinetic model was considered.71, 72 In this 395 
model, substrate (Pdx in the present case) molecules may bind an enzyme in either a 396 
particular sequence or randomly,73 but only one or more of the complexes produce the 397 
measured activity with independent rate constants kcat,i. Instantaneous equilibrium is a 398 
simplifying assumption of this model. The observation that the native P450cam system 399 
displayed Michaelis-Menten kinetics and that a mixture of 0.1 µM P450cam-PdR and 0.4 µM 400 
PdR showed Michaelis-Menten kinetics at lower Pdx concentrations but more fusion-like 401 
behavior at high Pdx concentrations led us to propose a model for the kinetics of the fusion 402 
enzyme. The model (Fig. 7A) is based on several assumptions: (a) PdR reduction to PdRr by 403 
NADH is orders of magnitude faster than reduction of ferric camphor-bound P450cam by 404 
Pdxr, (b) reduction of oxidized Pdx (Pdxo) to Pdxr by PdRr is fast under these conditions,12 (c) 405 
all P450cam domains are substrate-bound in the presence of 1 mM DL-camphor, and (d) 406 
P450cam:Pdxr binding occurs in preference to PdR:Pdxr binding, since dissociation of newly-407 
reduced Pdxr from PdR avoids product inhibition and allows the Pdxr to interact with 408 
P450cam as soon as possible.74, 75  409 
In this model the fused, camphor-bound ferric P450cam domain forms a complex 410 
with Pdxr with a dissociation constant Kd1. This complex can undergo electron transfer (kcat1) 411 
or the PdR domain can bind and reduce a Pdxo molecule as a Pdxr equivalent (Kd2), since 412 
Pdxo reduction is fast. The Pdxr:Fus:Pdxr complex can then either revert to Fus:Pdxr, or 413 
reduce the camphor-bound ferric P450cam domain (kcat2). When free PdR is added to the 414 
solution, this ternary complex becomes rare because free reductase competes for binding and 415 
reduction of Pdxo (Kd4, kcat3). Finally, the lowering of kcat with increasing fusion enzyme 416 
concentration suggested the formation of an inactive dimeric form. This possibility is taken 417 
into account by an equilibrium between the ternary Pdxr:Fus:Pdxr complex with another 418 
fusion enzyme molecule to form a catalytically inactive quaternary complex (Kd3), although 419 
other dimerization mechanisms may exist. Based on this model, the initial rate of NADH 420 
oxidation is given by Eq. 3: 421 
 422 
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 424 
where the Kd,i are the dissociation constants and the kcat,j are the rate constants for electron 425 
transfer for the complexes in Fig. 7A. 426 
In order to avoid over-fitting and over-parameterization, initial fitting to Eq. 3 varied 427 
only terms containing Kd1, Kd2, Kd3, kcat1, and kcat2 using the data collected in the absence of 428 
free PdR (Fig. 8A). The remaining parameters Kd4 and kcat3 were then fit to all the data while 429 
holding the other parameters fixed (Fig. 8B). This approach produced a reasonable fit for 430 
most of the data although there were some residual deviations at low Pdx concentration. 431 
The fitted values show that binding of the first Pdx molecule by the fusion enzyme is 432 
weaker than for the native system (Kd1 = 17 ± 2 µM compared to Km = 7.0 ± 0.8 µM), 433 
possibly because the PdR domain occludes the Pdx binding site in the fusion. In light of 434 
weaker camphor and potassium binding observed for the P450cam domain of the fusion 435 
compared to the native enzyme, weaker Pdxr binding is not surprising. The fitted value for 436 
kcat1 was 53 ± 7 s–1, close to the value of 64 ± 3 s–1 for kcat, the corresponding parameter for 437 
the Michaelis-Menten model of Pdxr binding and oxidation by native P450cam. 438 
The dissociation constant of the second Pdx binding event (Kd2 = 8 ± 2 µM) is smaller 439 
than the first, and identical within experimental error to the native system’s Km (Fig. 8A). 440 
Multi-site enzymes often display cooperativity, a phenomenon where successive binding 441 
events become increasingly thermodynamically favorable, due to conformational changes in 442 
the protein.76 Since the P450cam-PdR fusion is an artificial enzyme, it might not be expected 443 
that such an effect would be observed. However, the second Pdxr binding event may occur 444 
through several mechanisms, including nascent Pdxr moving from the fused PdR domain, or 445 
by Pdxr from bulk solution interacting with the P450cam domain. Therefore, the decrease in 446 
Kd2 compared to Kd1 could be attributed to a proximity effect arising from fusion of the Pdx-447 
reducing PdR domain to P450cam. 448 
Pdxr oxidation by the ternary complex (kcat2 = 42 ± 2 s–1) is marginally slower than by 449 
the binary complex (kcat1 = 53 ± 7 s–1). It is possible that the contribution to Kd2 from rapid 450 
Pdxo recruitment and reduction to Pdxr—which then could switch to the adjacent P450cam 451 
domain—by the PdR domain, while it manifests as tighter binding (Kd2), is a multi-step 452 
Eq. 3 
 16 
process which is slower than simple Pdxr oxidation by the P450cam domain, represented by 453 
kcat1. 454 
The catalytically inactive complex of two fusion enzyme molecules and two Pdx 455 
molecules could explain, in terms of self-inhibition, the empirical decrease in apparent k′cat as 456 
fused P450cam-PdR enzyme concentration increased (Fig. 6B), in contrast to native P450cam 457 
under similar conditions (Fig. 6A). The observed data provide no insight into the structure of 458 
the [Fus:Pdxr]2 dimer (Fig. 7A), although it may be envisioned as a homo-dimer of Fus:Pdxr 459 
hetero-dimers. The relatively small dissociation constant for this complex (Kd3 = 1.8 ± 0.2 460 
µM) may reflect an increase in the interfacial binding area in comparison to a single Fus:Pdxr 461 
interaction. 462 
The proposed model also suggests how the addition of free PdR dampens the 463 
sigmoidal NADH oxidation kinetics of the fused system by competing with the PdR domain 464 
in the fusion enzyme for Pdx molecules. The affinity of PdR for Pdx (Kd4 = 0.03 ± 0.01 µM, 465 
Fig. 8B) is shown to be two orders of magnitude higher than that of P450cam (7.0 ± 0.8 µM, 466 
Fig. 6A); such an extreme difference has been seen previously by calorimetry.77 This 467 
proposed model therefore explains the non-linearity of the PdR-supplemented fusion 468 
system’s hybrid NADH oxidation kinetics (Fig. 6C): at low Pdx concentrations, the 469 
proximity effect of the fused PdR domain is removed because Pdxo binds preferentially to the 470 
free, excess PdR. At higher Pdx concentrations, Pdxo binding with the fused PdR is more 471 
likely, especially as the native PdR becomes saturated, so the proximity effect (with its 472 
attendant potential for inactive dimer formation) is more prevalent. 473 
 474 
Conclusion 475 
Protein recognition and electron transfer between enzymes in class I CYP systems is still not 476 
fully understood.32 Slow kinetics have constrained development of these technologically 477 
promising enzymes for applications.78 We have shown that partial fusion of a class I CYP 478 
system can lend it favorable properties. Changes in the linker peptide and addition of 479 
common culture supplements enabled the production of the almost fully heme-incorporated 480 
CYP-FdR fusion. This system is catalytically active in vivo and in vitro. In addition to the 481 
convenience of such a fusion, the unusual kinetic properties allowed the construction of a 482 
reasonable model of binding events. This model may allow future improvements to the fused 483 
enzyme, and also facilitate better understanding of ferredoxin-to-CYP electron transfer. As 484 
such, partially fused class I CYP systems merit further investigation. Finally, given that PdR 485 
can show high activity for the reduction of non-native electron transfer ferredoxins from 486 
 17 
other CYP systems, such as Arx from Novosphingobium aromaticivorans and Pux from 487 
Rhodopseudomonas palustris,79, 80 fusions of CYP enzymes with PdR could be tested for 488 
activity reconstitution with native forms as well as engineered variants of these ferredoxins. 489 
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Table 1. Summary of heterologous expression conditions for P450cam-PdR fusion constructs 
and the resultant heme incorporation of the isolated enzyme as calculated by spectral 
decomposition of its electronic spectrum (see Materials & Methods). d-ALA: 5-
aminolevulinic acid, AFC: ammonium ferric citrate, RF: riboflavin, Camphor: DL-camphor, 
HemH: co-expression of E. coli ferrochelatase. 
 
d-ALA 
(µM) 
FeCl2 
(µM) 
AFC 
(mM) 
RF 
(µM) 
EDTA 
(mM) 
Camphor 
(mM) 
HemH Linker Heme 
(%) 
– – – – – – – LA 2.0 
100 10 – – – – – LA 5.8 
500 – – – – – – LA 26 
– 50 – – – – – LA 6.9 
500 50 – – – – – LA 40 
– – – – – 1 – LA 31 
– – – – 2 1 – LA 8.6 
100 – – – – – Yes LA 22 
1000 – 4 100 – 1 Yes L2 85 
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Fig. 1. Electron-transfer in wild type and artificially fused class I CYP systems. (A) After NADH 
oxidation by the ferredoxin reductase (FdR) electrons are shuttled singly by a ferredoxin (Fdx) to the 
cytochrome P450 (CYP) to catalyze oxygen insertion into a C–H bond. Since this is a relatively slow, 
intermolecular process, attempts have been made to fuse the three component proteins into a single 
polypeptide to improve kinetics.11 (B) Linear fusion of the P450cam system from Pseudomonas 
putida caused a reduction in camphor hydroxylation rate in vivo.42 (C) Fusion of the P450cam system 
to PCNA, a self-assembling hetero-trimer.44 (D) The reductase of the P450Rhf system from 
Rhodococcus rhodocrous has been systematically fused to a panel of class I P450s, reconstituting the 
activity of some of them.47 (E) The present work describes a partially fused P450cam system, with the 
amino-terminus of PdR connected to the carboxy-terminus of P450cam by a peptide linker, leaving 
Pdx free to shuttle electrons between the two domains. 
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Fig. 2. Design and construction of fused P450cam-PdR constructs. The plasmids for P450cam-
PdR expression went through three generations of construction. (A) The P450cam and PdR domains 
were to be linked by a peptide chain connecting the P450cam carboxy-terminus to the PdR amino-
terminus. The linker would be encoded in an artificial fused gene. (B) Two linkers were used. The 
first (LA) was based on work that fused P450scc (CYP11A1) and Adx for crystallization of the 
enzyme complex, where the AAKKT linker produced a functional fusion protein.59 The second (L2) 
contained 20 amino acid residues and was based on the linker found in naturally fused P450BM3 
(CYP102A1) from Bacillus megaterium. Both linkers were extended due to the incorporation of a 
SacI restriction site. (C) The plasmid pFusion, derived from pRSFDuet-1, was converted to pFusionH 
by insertion of the E. coli ferrochelatase gene (hemH) into the second multiple cloning site (MCS2). 
The third generation plasmid, pFusionH2, was constructed by swapping linker LA for linker L2 using 
inverse PCR and MEGAWHOP. 
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Fig. 3. Optimization of heme incorporation in fused P450cam-PdR. Heterologous expression 
conditions and inter-domain linker length were varied to increase heme incorporation of the 
P450cam-PdR fusion. (A-D) Heme incorporation for fusion enzymes prepared under several 
conditions was calculated by spectral decomposition of the electronic spectrum of the purified fusion 
enzyme based on the spectra of purified native P450cam and PdR. AFC: ammonium ferric citrate. 
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Fig. 4. In vivo activity of the fused P450cam-PdR system in TB medium. To test the camphor 5-
hydroxylase activity of the fused P450cam-PdR system in the presence of Pdx, E. coli BL21 (DE3) 
were transformed with pFusionH2 or pRSFDuet::camA::camC and pUC18::camB and induced in TB, 
a rich medium, in the presence of 40 µM IPTG and 1 mM DL-camphor. GC analysis was performed 
on ethyl acetate extracts of culture supernatant (three biological replicates) at several time points until 
24 h. (A) Typical GC analysis for culture supernatant from the fused system after 0 and 24 h 
incubation. (B) The abundance of DL-camphor, 5-exo-hydroxycamphor, 5-oxo-camphor, and indole 
were followed over time. FID = Flame ionization detector.  
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Fig. 5. Substrate binding of the fused P450cam-PdR enzyme. (A) Reduced, CO-bound P450cam-PdR 
fusion has a prominent 450 nm Sorét band, characteristic of the CYP superfamily; the shoulder at 420 
nm can be seen, indicative of the inactive P420 form. (B) The Sorét band of ferric P450cam-L2-PdR at 
419 nm shifted increasingly to 390 nm with DL-camphor concentration. (C) The maximal Sorét band 
shift for fused P450cam-PdR was lower than for native P450cam, and the calculated Kd was two-fold 
higher in high potassium solution. Lowering the potassium concentration reduced the camphor Kd for the 
fusion, mimicking the behavior seen previously in P450cam. (D) Fused P450cam-PdR also had a two-
fold higher dissociation constant, Kd, for potassium ion binding in the presence of excess DL-camphor. 
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Fig. 6. NADH oxidation kinetics of the reconstituted P450cam-L2-PdR fusion. NADH oxidation 
by fused P450cam-PdR in the presence of Pdx was measured and compared to the native system. (A) 
The native P450cam system shows Michaelis-Menten kinetics. (B) Hanes-Woolf plots showing the 
non-Michaelis-Menten behavior of the P450cam-L2-PdR fusion: low Pdx concentrations give a 
deviation from linearity, and best-fit kcat, k′cat, decreases as fusion concentration increases. Doping the 
system with PdR has similar but less pronounced behavior. (C) An equimolar amount of PdR was 
added to 0.5 µM P450cam-PdR and Pdx was titrated across a similar concentration range. The kinetic 
behavior was different, with lower Km and kcat values.   
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Fig. 7. A proposed model for NADH oxidation kinetics of the reconstituted P450cam-L2-PdR 
fusion. (A) Pdxr-to-P450cam electron transfer is the rate-limiting step of NADH oxidation. The native 
system conforms to the Michaelis-Menten model (green pathway). However, the P450cam-L2-PdR 
fusion deviates strongly from Michaelis-Menten behavior. An extended two-site sequential-binding 
model (green and black pathways) was proposed to explain the observed kinetics of the fused system. 
(B) Based on the proposed kinetic model, a function describing the initial rate of NADH oxidation in 
terms of enzyme concentrations could be derived, assuming instantaneous equilibrium. 
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Fig. 8. Best fit of the proposed kinetic model to the observed data. (A–B) The model appears to 
explain the decrease in observed kcat with increasing fusion concentration, along with apparent 
cooperativity at low Pdx concentrations. In addition, it explains the fused-native hybrid kinetics seen 
when the fusion was assayed in the presence of free PdR. 
